Pompe disease is an autosomal recessive lysosomal storage disorder characterized by progressive muscle weakness. The disease is caused by mutations in the acid α-glucosidase (GAA) gene. Despite the currently available enzyme replacement therapy (ERT), roughly half of the infants with Pompe disease die before the age of 3 years. Limitations of ERT are immune responses to the recombinant enzyme, incomplete correction of the disease phenotype, lifelong administration, and inability of the enzyme to cross the blood-brain barrier. We previously reported normalization of glycogen in heart tissue and partial correction of the skeletal muscle phenotype by ex vivo hematopoietic stem cell gene therapy. In the present study, using a codon-optimized GAA (GAAco), the enzyme levels resulted in close to normalization of glycogen in heart, muscles, and brain, and in complete normalization of motor function. A large proportion of microglia in the brain was shown to be GAA positive. All astrocytes contained the enzyme, which is in line with mannose-6-phosphate receptor expression and the key role in glycogen storage and glucose metabolism. The lentiviral vector insertion site analysis confirmed no preference for integration near proto-oncogenes. This correction of murine Pompe disease warrants further development toward a cure of the human condition.This publication reports that stem cell gene therapy using a codon-optimized gene encoding acid α-glucosidase (GAA) cures the mouse model of Pompe disease, a lysosomal storage disorder.

Additional Metadata
Keywords acid α-glucosidase, central nervous system, hematopoietic stem cell transplantation, lentiviral vector, murine Pompe disease, skeletal muscle
Persistent URL dx.doi.org/10.1016/j.omtm.2020.04.023, hdl.handle.net/1765/127067
Journal Molecular Therapy - Methods and Clinical Development
Citation
Stok, M, De Boer, H, Huston, M.W, Jacobs, E.H. (Edwin H.), Roovers, O, Visser, T.P, … Wagemaker, G. (2020). Lentiviral Hematopoietic Stem Cell Gene Therapy Corrects Murine Pompe Disease. Molecular Therapy - Methods and Clinical Development, 17, 1014–1025. doi:10.1016/j.omtm.2020.04.023